Abstract

In an effort to evaluate the therapeutic impact of oxiracetam in conjunction with repetitive transcranial magnetic stimulation, the current research endeavors to assess patients with mild cognitive impairment after craniocerebral injury. Over a period spanning from March 2020 to March 2023, 160 patients diagnosed with mild cognitive impairment were involved in this research and randomly separated into either the control group treated exclusively with oxiracetam or the study group receiving a combined treatment of oxiracetam and repetitive transcranial magnetic stimulation. The changes of intelligence, cognitive function and neurotransmitter indexes were observed. Upon completion of the treatment regimen, the study group displayed substantial increases in both mini mental state examination and Montreal cognitive assessment scores than the control group. Additionally, the study group exhibited markedly higher levels of neurotransmitters such as norepinephrine, serotonin and dopamine compared to the control (p<0.05). The improvement rate of the study group was remarkably higher at 88.75 % as compared to their counterparts in the control group who exhibited an improvement rate of 65.00 %. This difference was statistically significant between the two groups (p<0.05). The implementation of a combined treatment strategy featuring both oxiracetam and repetitive transcranial magnetic stimulation in patients diagnosed with mild cognitive impairment yielded promising results, effectively mitigating cognitive impairment, enhancing neurotransmitter function and expediting overall improvement of patient wellbeing.